Michael K. Lim
Palo Alto University · 779 works · 37,430 citations · h-index 79
Top works
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
- Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- Current state of immunotherapy for glioblastoma
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
- Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma
- Next-generation sequencing in neuropathologic diagnosis of infections of the nervous system
- Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord
- Mechanisms of immunotherapy resistance: lessons from glioblastoma
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
- Prospects of immune checkpoint modulators in the treatment of glioblastoma
- Glioma
- OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
- Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial